SCHEMBL5754134

SCHEMBL5754134

CC(C)[C@@H](NS(=O)(=O)c1ccc2nc(SCc3ccc(Cl)cc3)sc2c1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.52
GPR55 Q9Y2T6 1/20 0.52
MMP2 P08253 2/20 0.51
MMP1 P03956 1/20 0.51
MMP3 P08254 1/20 0.51
MMP7 P09237 1/20 0.51
MMP9 P14780 1/20 0.51
MMP13 P45452 1/20 0.51
TP53 P04637 3/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
THRB P10828 1/20 0.50
MEN1 O00255 1/20 0.47
CYP2C9 P11712 1/20 0.47
KMT2A Q03164 1/20 0.47
MMP12 P39900 1/20 0.47
HPGD P15428 1/20 0.47
MAPT P10636 2/20 0.46
PPARG P37231 1/20 0.46
PPARD Q03181 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5758844 0.92 MAPT (0.56) MMP13TP53ALDH1A1GAATHRB
SCHEMBL5756325 0.91 HTT (0.55) HTTGPR55TP53ALDH1A1GAA
SCHEMBL5757635 0.89 MAPT (0.53) MMP2MMP1MMP3MMP7MMP9
SCHEMBL5758777 0.86 HTT (0.54) HTTGPR55MMP2MMP1MMP3
SCHEMBL5756259 0.86 ALOX15 (0.53) HTTGPR55MMP13TP53ALDH1A1
SCHEMBL5759318 0.84 ALOX15 (0.52) HTTGPR55MMP13TP53ALDH1A1
SCHEMBL5756019 0.84 MAPT (0.53) HTTGPR55MMP2MMP1MMP3
SCHEMBL5755055 0.83 MEN1 (0.48) HTTGPR55MMP13TP53ALDH1A1
SCHEMBL5757339 0.82 PKM (0.56) HTTGPR55MMP2MMP9MMP13
SCHEMBL5754971 0.82 ALOX15 (0.50) HTTGPR55MMP13TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 HTT 3845/4885GPR55 4680/4885MMP2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.